In a nutshell This study observed the effect of different physical activities on measures like pain and cardiorespiratory fitness in patients receiving hormone therapy for breast cancer (BC). The study showed that aerobic and resistance training might positively impact cardiorespiratory fitness and pain in these patients. Some...
Read More
In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...
Read More
In a nutshell This study aimed to investigate the outcomes of accelerated partial breast irradiation (ABPI) with TomoTherapy (TT) after breast conservative surgery (BCS) in patients with invasive breast cancer. This study concluded that this treatment is safe and effective with good long-term outcomes in these patients. Some...
Read More
In a nutshell This study compared whole breast irradiation (WBI) to partial breast irradiation (PBI) following breast-conserving surgery (BCS) in patients with low-risk breast cancer. The study showed similar survival between the 2 treatments, while PBI gave better cosmetic results. Some background Patients with low-risk breast...
Read More
In a nutshell This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including breast cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in...
Read More
In a nutshell This study was carried out to examine the effectiveness of olaparib (Lynparza) for the treatment of metastatic breast cancer (MBC; cancer that has spread) with gene mutations (abnormalities). The authors found that this treatment was effective for patients with MBC with BRCA1/2 mutations. Some background Breast cancer (BC) is one of the...
Read More
In a nutshell This study compared the safety of two hormonal medications used to treat breast cancer, tamoxifen (Nolvadex) and letrozole (Femara). This study found that tamoxifen was associated with an increased risk of blood clots, while letrozole was associated with an increased risk of angina and heart attacks. Some background Hormone-positive...
Read More
In a nutshell This study will investigate the safety and effectiveness of tiragolumab combined with atezolizumab (Tecentriq) and chemotherapy to treat triple-negative breast cancer (TNBC). The main outcome will be the occurrence of side effects and the objective response rate (ORR). The details Breast cancer (BC) is the most...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This study was carried to examine the effectiveness of using chest computed tomography (CT) for the screening of osteoporosis (OP) and predicting the risk of fractures (bone breaks) in patients with breast cancer (BC). The authors found that CT can be used for predicting OP and determining the risk of fractures in these...
Read More
In a nutshell The study evaluated whether Breast Cancer Index (BCI) can predict benefits from extended endocrine therapy (EET) in patients with hormone-receptor-positive (HR+) early-stage breast cancer (BC). The authors found that BCI can predict which patients would benefit from 10 years of EET. Some background Endocrine therapy (ET) prevents tumor...
Read More
In a nutshell This study is looking to trial the addition of a new form of vaccine called a neoantigen vaccine in combination with nab–paclitaxel (Abraxane), duvalumab (Imfinzi), and tremelimumab (CP-675,206), in patients with metastatic triple-negative breast cancer (mTNBC). The main outcome that will be measured is survival without the...
Read More
